Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Genmab ( (GMAB) ).
On March 2, 2026, Genmab A/S filed a Form 6-K in the United States to report a correction to an earlier company announcement regarding insider transactions in its shares. The filing clarifies that the share price used for several management-related transactions was DKK 1,867.50, rather than the erroneously reported DKK 0.00, and confirms the report will be incorporated by reference into existing share-based compensation registration statements.
The corrected disclosure covers the March 2, 2026 acquisition of Genmab shares by President and CEO Jan van de Winkel, CFO Anthony Pagano, and board member Mijke Zachariasse, all arising from the vesting and net settlement of restricted stock units granted in February 2023. The move underscores the company’s adherence to regulatory transparency on executive equity awards and provides investors with accurate information on insider dealings and management’s equity-linked compensation.
The most recent analyst rating on (GMAB) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Neutral.
The score is supported by strong financial performance (rapid growth, high margins, solid cash generation) and a constructive earnings outlook with meaningful pipeline catalysts, but is held back by the sharp 2025 leverage increase and weaker earnings quality signals, plus bearish near-term technical momentum despite oversold readings.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is a Denmark-based biotechnology company listed on Nasdaq under the ticker GMAB, specializing in the development of antibody-based therapeutics for treating cancer and other serious diseases. The company operates globally, with its headquarters in Valby, Copenhagen, and is a prominent player in the biopharmaceutical sector focused on innovative oncology treatments.
Average Trading Volume: 1,719,155
Technical Sentiment Signal: Buy
Current Market Cap: $18.01B
See more insights into GMAB stock on TipRanks’ Stock Analysis page.